CORDIS
EU research results

CORDIS

English EN
Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE

Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE

Objective

Loco-regional treatment is the mainstay of cancer cures in non small lung and head and neck cancer. For advanced stage cancer, dose intense multimodality treatment is required yet affected by substantial side effects. Our aim is to improve treatment outcome in locally advanced head and neck and lung cancer patients by:
1. Optimizing local control by introducing novel radiation techniques resulting in redistribution of the radiation dose, creating inhomogeneous dose distribution towards the most active part of the tumour instead of conventional homogenous doses. This redistribution can be performed without increase of toxicity. As recently reported radiation accidents in the US demonstrate, QA is of outmost importance for safe radiation delivery in complex treatments. To assure accurate delivery over time, we will monitor both the patient’s geometry as well as the delivered dose using image guided adaptive plan modifications and 3D in-vivo dosimetric verification.
2. Maximizing the benefit of combined modality treatment
Both cisplatin and Cetuximab in combination with radiotherapy have shown to improve local control and survival but both drugs have severe side effects. As these drugs are not active in all patients, there is a large need to select patients which are sensitive to either drug. For this purpose the uptake of Cetuximab will be estimated by imaging tumour uptake with Zr89 labelled Cetuximab, while cisplatin sensitive tumours can be selected by biomarkers. This part was stopped in May 2014.
This proposal will:
1 optimise efficiency by selecting patients on treatment specific tumour response predictors and tailoring radiation to most active parts of the tumour.
2 improve quality of life by withholding ineffective, toxic treatments and redistribution of dose.
3 decrease community costs by reserving expensive treatments for those who will benefit.
This will be studied in randomized phase II clinical trials in top European institutes, followed by phase III trials outside this proposal.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Address

Plesmanlaan 121
1066 Cx Amsterdam

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 347 168,15

Administrative Contact

Henri Van Luenen (Dr.)

Participants (14)

Sort alphabetically

Sort by EU Contribution

Expand all

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 424 688,80

EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY

Belgium

EU Contribution

€ 161 077,20

STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC

Netherlands

EU Contribution

€ 937 130,40

INSTITUT CATALA DE LA SALUT

Spain

EU Contribution

€ 309 297,60

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 685 575,60

MAASTRO INNOVATIONS BV

Netherlands

EU Contribution

€ 165 825

RAYSEARCH LABORATORIES AB

Sweden

EU Contribution

€ 261 788,25

THE CHRISTIE NHS FOUNDATION TRUST

United Kingdom

EU Contribution

€ 78 384

INSTITUT GUSTAVE ROUSSY

France

EU Contribution

€ 486 285,20

STICHTING ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands

STOCKHOLMS LANS LANDSTING

Sweden

EU Contribution

€ 33 188,40

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 23 706

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 56 894,40

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 23 706

Project information

Grant agreement ID: 257144

Status

Closed project

  • Start date

    1 April 2011

  • End date

    30 September 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 929 822,20

  • EU contribution

    € 5 994 715

Coordinated by:

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands

This project is featured in...